Endocrinology Summit 2018 : Viability of the Impact of Dostinex on the Administration of Patients with Prolactinomas- Mukhammedaminova Diyora- Tashkent Pediatric Medical Institute

Prolactinomas are the most well-known pituitary tumors, comprising around 68% of all suggestive pituitary adenomas. Microadenomas are available around four to multiple times more than macroadenomas. Reason: to survey the adequacy of the effect of dopamine agonists (Dostinex) on the administration of patients with prolactinomas. Materials and techniques: We analyzed 40 patients matured from 18 to 45, 25 of them (62.5%) with microprolactinomas (bunch 1) and 15 (37.5%) with macroprolactinomas (bunch 2). The conclusion of prolactinoma depends on re-deciding the degree of hormones in the blood, alongside x-beam proof of a pituitary tumor, as a rule with attractive reverberation imaging (X-ray) of the pituitary. Results. Galactorrhea and sporadic feminine cycle were seen in all patients (100%). 6 (24%) of the 25 patients in bunch 1 and all patients from bunch 2 (100%) encountered a reduction in vision (narrowing of the visual fields). 12 (48%) of the 25 patients in bunch 1 and all patients from bunch 2 (100%) had migraines. Regarding the abovementioned, we suggested the Dostinex (Cabergoline) in portion of 0.25-1 mg for 9 months.

Share This Article